

FIG. 1A and FIG. 1B  
Hybrid ImmunoCapture (HIC) Assay




Fig. 1A






Fig. 1B


**FIG. 2: Plasma Lp-PLA2 Activity in HIC-ThioPAF Assay (2c10 as capturing mAb)**




**FIG. 3: Plasma Lp-PLA2 Activity in HLC-ThioPAF Assay (B200.1 as capturing mAb)**



**FIG. 4: Plasma Lp-PLA2 Activity in HIC-ThioPAF Assay (B501.1 as capturing mAb)**




**FIG. 5: Plasma Lp-PLA2 Activity in HIC-MNP Assay (2c10 as capturing mAb)**




○ = with 1-myristoyl-2-(4-nitrophenylsuccinyl) phosphatidylcholine substrate (MNP)  
□ = without 1-myristoyl-2-(4-nitrophenylsuccinyl) phosphatidylcholine substrate

**FIG. 6: Plasma Lp-PLA2 Activity In Commercial ThioPAF Assay**



**FIG. 7: Plasma sample background in Improved ThioPAF Assay, with DTNB but w/o substrate added**



○ = without 2-thio PAF substrate; with DTNB added

**FIG. 8: Plasma Lp-PLA2 Activity in Improved ThioPAF Assay**

